Wave Life Sciences Ltd. (WVE)

Wave (WVE) Q2 Revenue Drops 56%

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Erik Ingelsson - Chief Scientific Officer Kate Rausch - Head of Investor Relations Kyle B.

Wave Life Sciences (WVE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.25 per share a year ago.

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company's second quarter 2025 financial results and provide business updates.

Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying opportunity for a risk-on investor. Wave is partnered with GSK over its AATD program which recently demonstrated proof-of-concept and opens up the possibility of triple-digit million milestone payments.

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Salim Syed - Mizuho Catherine Novack - Jones Research Ananda Ghosh - HC Wainwright and Company Lisa Walter - RBC Madison El-Saadi - B.

Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement in TTR, substantial improvements in muscle health; NDA submission for accelerated approval with monthly dosing planned for 2026 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $243.1 million as of March 31, 2025, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass.

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates.

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033.